LCS1269: A New Anti-Glioblastoma Drug
Author Information
Author(s): Nikolay Kalitin, Natalia Koroleva, Anna Lushnikova, Maria Babaeva, Nadezhda Samoylenkova, Ekaterina Savchenko, Galina Smirnova, Yulia Borisova, Alexander Kostarev, Aida Karamysheva, Galina Pavlova, Anna Carbone
Primary Institution: N.N. Blokhin National Medical Research Center of Oncology
Hypothesis
LCS1269, a glycosylated indolocarbazole, may have anti-glioblastoma effects through cell cycle modulation.
Conclusion
LCS1269 shows significant anti-glioblastoma effects, outperforming temozolomide, by inducing G2 phase arrest and modulating CDK1 activity.
Supporting Evidence
- LCS1269 showed a significant cytotoxic effect against glioblastoma cell lines.
- LCS1269 treatment caused severe G2 phase arrest in a dose-dependent manner.
- LCS1269 was more effective than temozolomide in reducing glioblastoma cell viability.
- LCS1269 suppressed tumor growth in a mouse model of glioblastoma.
Takeaway
LCS1269 is a new medicine that helps fight brain cancer by stopping cancer cells from dividing.
Methodology
The study used MTT assays, flow cytometry, fluorescence microscopy, quantitative RT-PCR, and Western blotting to evaluate the effects of LCS1269 on glioblastoma cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website